Scarica l'app Stockscreener
3.98
4.56%
-0.19
Dopo l'orario di chiusura:
4.00
0.02
+0.50%
Precigen Inc Borsa (PGEN) Ultime notizie
These analysts boost their forecasts on Precigen following Q4 results - MSN
Wall Street bullish on Precigen (PGEN) as the company transitions to commercial stage - MSN
Is Precigen Inc. (PGEN) The Best Healthcare Penny Stock to Buy? - Yahoo Finance
Aug Closing: Whats the fair value of Precigen Inc stockMarket Performance Recap & Expert Curated Trade Ideas - baoquankhu1.vn
Take Profit: Is Precigen Inc a turnaround storyWeekly Gains Summary & Real-Time Chart Breakout Alerts - baoquankhu1.vn
Precigen gains after 2025 results on Papzimeos' outlook - MSN
Precigen, Inc. (PGEN) poised for growth on respiratory papillomatosis treatment prospects - MSN
Wall Street Bullish on Precigen (PGEN) As the Company Transitions to Commercial Stage - Insider Monkey
Take Profit: What are Precigen Incs recent SEC filings showingGap Down & Weekly High Conviction Trade Ideas - baoquankhu1.vn
Precigen Reports 'Robust Uptake' of New Drug for Rare Respiratory Disease; First Quarter Revenue Expected to Top $18 Million - ACCESS Newswire
Precigen (PGEN) price target increased by 11.76% to 9.69 - MSN
CapEx per share of Precigen Inc – SWB:I5X - TradingView — Track All Markets
PGEN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Precigen sees Q1 revenue exceeding $18M, consensus $20.8M - Yahoo Finance
Precigen reports $3.4M in PAPZIMEOS sales for Q4 2025 By Investing.com - Investing.com Australia
Precigen Reports Strong Demand for New Rare Disease Drug - National Today
Precigen (PGEN) Eyes Revenue Growth with PAPZIMEOS Success - GuruFocus
Precigen (PGEN) Sees Strong Demand for Papzimeos Immunotherapy - GuruFocus
(PGEN) Precigen Expects Q1 Revenue to Exceed $18M, vs. FactSet Est of $20.8M - marketscreener.com
Precigen reports $3.4M in PAPZIMEOS sales for Q4 2025 - Investing.com
Precigen Reports 'Robust Uptake' of New Drug for Rare Respirator - GuruFocus
Precigen, Inc. (PGEN) Poised for Growth on Respiratory Papillomatosis Treatment Prospects - Yahoo Finance
Precigen (PGEN) Is Up 7.4% After Surging Revenue And Wider 2025 Losses Are Reported – Has The Bull Case Changed? - Sahm
Precigen Stock Hits Day Low of $3.94 Amid Price Pressure - Markets Mojo
PGEN Should I Buy - Intellectia AI
Precigen to Participate in H.C. Wainwright Virtual Fireside Chat - Intellectia AI
Insider Selling: Precigen (NASDAQ:PGEN) Director Sells 4,772,781 Shares of Stock - MarketBeat
PGEN SEC FilingsPrecigen Inc 10-K, 10-Q, 8-K Forms - Stock Titan
PGEN.O Technical Analysis & Stock Price Forecast - Intellectia AI
PGEN PE Ratio & Valuation, Is PGEN Overvalued - Intellectia AI
Precigen, Inc. (NASDAQ:PGEN) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Precigen, Inc. (NASDAQ:PGEN) Q4 2025 earnings call transcript - MSN
PGEN.O Stock News Today | Earnings, Events & Price Alerts - intellectia.ai
4,772,781 Precigen (PGEN) shares sold by entities tied to Randal Kirk - Stock Titan
Randal J. Kirk (PGEN) entities sell 4.8M shares, still hold over one-third stake - Stock Titan
Precigen Details Papzimeos Commercial Launch, Hub Growth and J-Code Catalyst at H.C. Wainwright Chat - MarketBeat
Precigen (NASDAQ:PGEN) Stock Price Up 11.2%What's Next? - MarketBeat
Precigen to Participate in a Fireside Chat with H.C. Wainwright on March 31 - StreetInsider
[144] PRECIGEN, INC. SEC Filing - Stock Titan
Precigen (NASDAQ:PGEN) Shares Down 9%Time to Sell? - MarketBeat
HC Wainwright Estimates Precigen's Q1 Earnings (NASDAQ:PGEN) - MarketBeat
0.81%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):